Diversify Advisory Services LLC Purchases New Shares in Castle Biosciences, Inc. $CSTL

Diversify Advisory Services LLC purchased a new position in Castle Biosciences, Inc. (NASDAQ:CSTL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,932 shares of the company’s stock, valued at approximately $389,000. Diversify Advisory Services LLC owned 0.05% of Castle Biosciences as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CSTL. Amundi grew its position in shares of Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares during the period. AQR Capital Management LLC lifted its position in Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after acquiring an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Castle Biosciences by 34.7% in the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after purchasing an additional 8,992 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Up 1.9%

NASDAQ:CSTL opened at $32.93 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The firm has a market cap of $1.01 billion, a P/E ratio of -49.89 and a beta of 0.98. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28. The firm has a 50-day simple moving average of $25.64 and a two-hundred day simple moving average of $25.47.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. Analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on CSTL. Roth Capital initiated coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price for the company. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. BTIG Research raised their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. KeyCorp set a $35.00 price objective on Castle Biosciences in a research report on Friday, May 29th. Finally, Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Insider Activity at Castle Biosciences

In other news, insider Tobin W. Juvenal sold 17,310 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $29.31, for a total value of $507,356.10. Following the completion of the transaction, the insider owned 80,725 shares in the company, valued at $2,366,049.75. The trade was a 17.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 20,356 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $31.11, for a total value of $633,275.16. Following the transaction, the insider directly owned 21,479 shares in the company, valued at approximately $668,211.69. The trade was a 48.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 136,305 shares of company stock valued at $3,841,714. 6.10% of the stock is owned by corporate insiders.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.